# Beijing Linking Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-linking-medical-technology-co

- Industry: Software
- Headquarters: Beijing, China
- Website: www.linkingmed.com
- Total disclosed funding: $15M
- Latest round: Series A (Oct 30, 2019)
- Investors on record: 7

## About

Beijing Linking Medical Technology Co., Ltd. specializes in artificial intelligence-driven solutions for tumor radiation therapy, offering innovative software systems that enhance the accuracy of medical treatments.Founded in 2016 in Beijing, China, Beijing Linking Medical Technology Co., Ltd. focuses on developing AI solutions for tumor radiation treatment. The company raised RMB 40 million in a Series A funding round on October 30, 2019, led by Grains Valley Venture Capital, with participation from Binhai VC Capital and Linear Venture. Hua Zhang serves as the CEO and founder, bringing expertise in medical technology to the firm's operations.Beijing Linking Medical Technology Co., Ltd. specializes in artificial intelligence-driven solutions for tumor radiation therapy. Their core product offerings include advanced software systems for contour drawing, treatment planning, intelligent quality control, and tumor information management. These products utilize AI and cloud computing technologies to deliver automated organ delineation, target area identification, and radiation treatment plans, significantly enhancing operational efficiency for healthcare providers. The company serves hospitals, radiation therapy departments, and third-party imaging centers, providing essential tools that aid medical professionals, including radiation oncologists and medical physicists, in delivering precise and effective radiation treatments. Geographically, their products are positioned within various Chinese markets, catering to healthcare institutions across the nation.Beijing Linking Medical Technology Co., Ltd. generates revenue primarily through B2B transactions, offering subscription-based services and partnership agreements to its clientele in the healthcare sector. The company’s flagship offerings, such as the AiQA quality control system and the RAIC tumor information system, are integral to their service portfolio, enabling healthcare facilities to improve treatment accuracy and operational workflows. As part of their revenue structure, clients typically enter agreements for software licensing and support services, which are structured to facilitate seamless integration within existing clinical systems. While specific pricing plans for their products are not disclosed, the transactional model is designed to provide ongoing support and updates, fostering long-term relationships with healthcare providers.Beijing Linking Medical Technology Co., Ltd. plans to leverage its recent Series A funding of RMB 40 million, raised in October 2019, to accelerate the development of new AI-driven products for tumor treatment and expand its market reach. The company is targeting further expansion into additional Chinese markets and aims to introduce innovative software solutions by the end of 2023, enhancing the capabilities of radiation therapy for healthcare providers.

## Funding rounds

- Series A, Oct 30, 2019, $5.7M — Grains Valley Venture Capital, Linear Capital, Tianjin Binhai Venture Capital
- Series A, May 3, 2018, $7.9M — DHVC, Linear Capital
- Series A, Jul 5, 2017 — Linear Capital
- Angel, Dec 14, 2016, $1.7M — CASH Capital, Xike Angel Fund, AnlongMed Investment

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Angel
- Xike Angel Fund (https://capitalatlas.ai/funds/xike-angel-fund) — Angel
- AnlongMed Investment — Angel
- Linear Capital (https://capitalatlas.ai/funds/linear-capital) — Series A
- DHVC (https://capitalatlas.ai/funds/dhvc) — Series A
- Grains Valley Venture Capital (https://capitalatlas.ai/funds/grains-valley-venture-capital) — Series A
- Tianjin Binhai Venture Capital (https://capitalatlas.ai/funds/tianjin-binhai-venture-capital) — Series A